FRIDAY, DECEMBER 14, 2018

Transcription

1 FRIDAY, DECEMBER 14, :00-7:10am Day Two Welcome Ash Tewari, MBBS, MCh RADICAL PROSTATECTOMY Panelists: Arul Chinnaiyan, MD, PhD; Douglas Scherr, MD; Prasanna Sooriakumaran, MD, PhD; Ofer Yossepowitch, MD 7:10-7:25am 7:25-7:35am 7:35-7:45am 7:45-8:00am 8:00-9:30am 9:30-9:40am 9:40-9:55am 9:55-10:10am 10:10-10:20am Chasing Complications Following RALP Francesco Montorsi, MD Role of Surgery in Advanced Disease and Salvage Lymph Node Dissections Vincent Laudone, MD Positive Margins After RARP Peter Wiklund, MD, PhD Audience Response Question with App BREAK / VISIT EXHIBITS 3D Live Surgery: Robot-Assisted Radical Prostatectomy Surgeon: Ash Tewari, MBBS, MCh Moderators: Ketan K. Badani, MD; Francesco Montorsi, MD Panelists: Michael Cookson, MD; Reza Ghavamian, MD; Francesco Porpiglia, MD Management of Lymph Node-Positive Prostate Cancer and Neoadjuvant Systemic Therapy in Localized Prostate Cancer Brian Chapin, MD Radical Prostatectomy in Oligometastatic Disease: Experience from the UK RCT TRoMbone Prasanna Sooriakumaran, MD, PhD The Role of Local Therapy in Oligometastatic PCa Markus Graefen, MD Cytoreductive Radical Prostatectomy in Men with M1a or M1b Disease Isaac Kim, MD, PhD SURS Panel Discussion NAILING PROSTATE CANCER: WHICH TECHNIQUES, WHY, WHEN AND HOW? Panelists: Erik Goluboff, MD; Ashok Hemal, MD, MCh; Michael Herman, MD; John Sfakianos, MD Page 1/5

2 10:20-10:35am 10:35-10:50am 10:50-11:05am 11:05-11:20am 11:20-11:45am 11:45-12:00pm 12:00-12:10pm 12:10-1:15pm Outpatient Prostatectomy David Lee, MD Retzius-Sparing Trans-Douglas Radical Prostatectomy Markus Hohenfellner, MD 3D Image-Guided Surgery in Prostate Cancer: From Cognitive to Augmented Reality Procedures Francesco Porpiglia, MD Less is More for Prostate Cancer Abhay Rane, OBE Robot-Assisted Radical Prostatectomy Ash Tewari, MBBS, MCh Perineal Robotic Prostatectomy Jihad Kaouk, MD Q&A (Radical Prostatectomy) LUNCH DEBATE: CREED 2: Battle of the Stars: Radiotherapy vs. Surgery For Locally Advanced and Advanced Prostate Cancer Moderator: Peter Wiklund, MD, PhD Audience Response Question with App 1:15-1:25pm 1:25-1:35pm 1:35-1:45pm Surgery: Prasanna Sooriakumaran, MD, PhD Radiotherapy: Mack Roach, III, MD Rebuttal Audience Response Question with App MAIN AFTERNOON SESSION I: ADVANCED PROSTATE CANCER Moderators: Markus Hohenfellner, MD; David Lee, MD; Mani Menon, MD; Abhay Rane, OBE 1:45-2:00pm Recent Advances in Management of Advanced Prostate Cancer William Oh, MD Page 2/5

3 2:00-2:15pm 2:15-2:30pm 2:30-2:40pm 2:40-2:55pm 2:55-3:05pm 3:05-3:20pm 3:20-3:35pm 3:35-3:45pm 3:45-4:00pm 4:00-4:05pm Promising Clinical Trials in Prostate Cancer Cora Sternberg, MD Biomarkers and Immunotherapy Susan F. Slovin, MD, PhD Precision Focal Prostatectomy Mani Menon, MD The Online Urologist: From Separating Signal Noise in Keeping with Research, to Boosting Referrals, Social, Mobile, and Machine Learning Technologies are Transforming Medicine Nate Gross, MD The QOL Comparison Between Open vs. Robotic Prostatectomy Misop Han, MD Open vs. Robotic Prostatectomy: Lessons Learned from the Swedish LAPPRO Trial Olof Akre, MD, PhD Radiotherapy in Prostate Cancer Michael Zelefsky, MD Why is it Important for Urology to Treat Castrate-Resistant Prostate Cancer? Mitchell Benson, MD 20 Years Follow Up from the SPCG4 Study: Surgery vs. Watchful Waiting Gunnar Steineck, MD, PhD Q&A SEXUAL HEALTH FOLLOWING PROSTATECTOMY Panelists: Natan Bar-Chama, MD; Barbara Chubak, MD; Doron Stember, MD; Atsushi Takenaka, MD, PhD; Robert Valenzuela, MD 4:05-4:20pm 4:20-4:35pm 4:35-4:50pm Orgasmic Dysfunction Following RARP Atsushi Takenaka, MD, PhD Stem Cells and Cytokines: Hope or Hype? Reviewing the Evidence for the Use of These for Prophylaxis Against and Treatment of Post-Prostatectomy ED Barbara Chubak, MD Sexual Function After RALP Doron Stember, MD Page 3/5

4 4:50-5:05pm 5:05-5:20pm Emerging Treatment Options for Post-Prostatectomy Climacturia Robert Valenzuela, MD Treatment of Male Hypogonadism Using Non-Testosterone Therapies Natan Bar-Chama, MD AFTERNOON SESSION II: INNOVATIONS IN ONCOLOGY Moderators: Mani Menon, MD; Gustavo Stolovitzky, PhD; Ash Tewari, MBBS, MCh 5:20-5:35pm 5:35-5:50pm 5:50-6:05pm 6:05-6:15pm Gene-Oncogene Interactions Carlos Cordon-Cardo, MD, PhD Current Status of Immune Therapy for Prostate Cancer Daniel Petrylak, MD Awards Ceremony Closing Remarks Ash Tewari, MBBS, MCh Page 4/5

5 FRIDAY, DECEMBER 14, 2018 BREAKOUT SESSION: IMMUNOTHERAPY & TUMOR MICROENVIRONMENT (PART II) Moderators: Jeffrey Bockman, PhD; Daniel Petrylak, MD 1:15-1:25pm 1:25-1:28pm 1:28-1:38pm 1:38-1:41pm 1:41-1:51pm 1:51-1:54pm 1:54-2:04pm 2:04-2:07pm 2:07-2:17pm 2:17-2:20pm 2:20-2:30pm 2:30-2:33pm 2:33-2:43pm 2:43-2:46pm Management of Incontinence After Radiation or Surgery Rajveer S. Purohit, MD, MPH Q&A (Management of Incontinence After Radiation or Surgery) Linking Scientific and Clinical Issues to Commercial/Strategic Considerations Jeffrey Bockman, PhD Q&A (Linking Scientific and Clinical Issues to Commercial/Strategic Considerations) Oligometastases and New Therapies for Bone Metastatic Prostate Cancer Alexander Kirschenbaum, MD Q&A (Oligometastases and New Therapies for Bone Metastatic Prostate Cancer) Novel Therapeutic Targeting of Advanced Cancer Natasha Kyprianou, PhD Q&A (Novel Therapeutic Targeting of Advanced Cancer) Tumor Suppressor, PTEN s Role in Prostate Cancer Progression Sait Ozturk, PhD Q&A (Tumor Suppressor, PTEN s Role in Prostate Cancer Progression) Urinary Adverse Events After Prostate Cancer Treatment (RP, RT, etc.) Jaspreet Sandhu, MD Q&A (Urinary Adverse Events After Prostate Cancer Treatment) Science that Underlies Prostate Cancer Racial Disparity Isaac Powell, MD Q&A (Science that Underlies Prostate Cancer Racial Disparity) Page 5/5

6 2:46-2:56pm 2:56-2:59pm 2:59-3:09pm 3:09-3:12pm 3:12-6:15pm Teamwork and Safety Conversations to Prevent Wrong Site Surgery Amanda Rhee, MD Q&A (Teamwork and Safety Conversations to Prevent Wrong Site Surgery) Socioeconomic Implications of Prostate Cancer Therapy Deepak Kapoor, MD Q&A (Socioeconomic Implications of Prostate Cancer Therapy) JOIN THE MAIN SESSION Page 6/5